NewLink Genetics announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, has been accepted for poster presentation at the American Association for Cancer Research, or AACR.
https://thefly.com/landingPageNews.php?id=2871689
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.